MedTrace Logo

3BNC117 and 10-1074 in ART-treated Individuals

NCT03526848 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-10-01

No results posted yet for this study

Summary

The proposed study is a phase 1, open label, randomized study to evaluate the safety and antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on combination antiretroviral therapy (ART) and during an analytical interruption of ART.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

3BNC117

Intravenous infusion of 3BNC117

DRUG

10-1074

Intravenous infusion of 3BNC117

OTHER

Analytical treatment interruption

Analytical treatment interruption

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Ragon Institute of MGH, MIT and Harvard

    collaborator OTHER

  • Montefiore Medical Center

    collaborator OTHER

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Marina Caskey, MD · The Rockefeller University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-05
Primary Completion
2021-09-30
Completion
2022-02-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526848 on ClinicalTrials.gov